Table 1.

Summary of recent placebo and active control trials of betahistine

Reference	N	Methodology	Diagnosis	Treatment	Duration
Albera et al 2003	(52)	Double-blind, randomized, muliticenter	Recurrent vetibular vertigo	Betahistine Flunarazne	8 weeks	Betahistine significantly more effective then flunarizine on DHI and physical, functional and functional subscores.
Mira et al 2003	144	Double-blind, multi-center, randomized, parallel group	Ménière’s ‘s disease or paroxysmal position vertigo of possible vascular origin	Placebo Betahistine 16 mg tid	3 months	Frequency, intensity and duration of attacks significantly reduced compared with placebo. Physician’s judgment and patient’s opinion of efficacy and acceptability favored betahistine
Novotny and Kostrica 2002	82	randomized, double-blind	Ménière’s disease	Betahistine 12 mg tid cinnarizine, 20 mg + dimenhydrinate, 40 mg tid	12 weeks	Highly significant reduction in vertigo symptoms, no difference between treatments. Significant improvement in hearing function noted for cinnarizine + dimenhydrinate
Cirek et al 2005	61	double-blind, comparative, single center	peripheral vestibular vertigo	Betahistine 12 mg tid cinnarizine 20 mg + dimenhydrinate 40 mg tid	4 weeks	Significantly greater reduction in vertigo score with cinnarizine+ dimenhydrinate than with betahistine